Alcon Inc.

ALC | NYSE

Price Alert Chart Builder DCF Calculator

$64.87

-$0.17 (-0.26%)

At close: Sep 21, 2026, 4:00 PM ET

$64.87

$0 (0.00%)

After-hours: Sep 21, 2026, 5:31 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Dividends Profile

-0.26%

(1D)

Rating

Updated: Aug 25, 2026

49.4

Fundamentals Average

Market Sentiment Neutral

Moat Narrow

Full Analysis

Key Statistics

Market Data

Market Cap $31.64B

1D Range

64.85 65.83

52W Range

61.84 87.64

Valuation (TTM)

PE 49.90

PB 1.47

EV/EBITDA 20.10

Valuation (NTM)

Forward PE 16.42

Forward PEG 3.72

Price Target $73.43

Cash Flow

FCF Yield 5.3%

SBC Adj. FCF Yield 5.6%

SBC Impact -4.5%

Margins

Gross Margin 56.5%

Operating Margin 9.9%

FCF Margin 15.6%

Growth (CAGR)

Revenue 3Y | 5Y 6.0% | 6.7%

Dil EPS 3Y | 5Y 21.8% | 28.6%

FCF 3Y | 5Y 73.8% | 40.5%

Returns

ROA 2.1%

ROE 2.9%

ROIC 3.2%

Financial Health

Net Debt

$3.26B

Current Ratio 2.09

Interest Coverage 5.13

Dividends

Div Yield 0.55%

Payout Ratio 27.6%

FCF Payout Ratio 10.0%

All Key Statistics

Loading financial charts...

Profile

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumenta...

Sector Healthcare

Industry Medical - Specialties

Employees 25,000

IPO Date Apr 8, 2019

Website www.alcon.com

Fiscal Year January - December

Full Company Profile

Latest News

18 days ago · zacks.com

Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?

Alcon's acquisitions, partnerships and new product launches support growth, but tariffs and intense competition remain key risks.

19 days ago · seekingalpha.com

Alcon: A Re-Rating In Eyesight

Alcon is a structurally advantaged ophthalmology leader with a durable equipment-to-consumables model and strong recurring revenue streams. At $72, ALC trades at ~18x forward earnings, reflecting mid-teens EPS growth but pricing in neither margin expansion nor pipeline optionality. Management targets 25% core operating margin by FY2027E, with current core EPS guidance raised to +12–15% growth and significant capital returns underway.

27 days ago · businesswire.com

Alcon Prices EUR 500 Million Senior Notes Offering

GENEVA--(BUSINESS WIRE)--Alcon Prices EUR 500 Million Senior Notes Offering.

1 month ago · seekingalpha.com

Alcon: A Strong Company Trading Close To Its Intrinsic Value, Buy

Alcon reported strong core operating profit (barring a one-time non-cash $402 million charge) during the quarter, up 17%. The company raised its full-year 2026 profit forecast for the second consecutive quarter. My DCF valuation states the stock is undervalued by 5.52%. I rate ALC a buy.

1 month ago · seekingalpha.com

Alcon Inc. (ALC) Q2 2026 Earnings Call Transcript

1 month ago · zacks.com

Alcon's Q2 Earnings and Revenues Surpass Estimates, Stock Climbs

ALC's Q2 earnings and sales beat estimates as equipment and ocular health gains lift results, while the company raises its 2026 EPS outlook.

1 month ago · reuters.com

Eye care company Alcon raises profitability outlook, cuts tariff hit estimate

Swiss-American eye care company Alcon on Monday hiked its profit guidance and lowered ‌its estimate for the full-year tariff impact to $40 million to $90 million, factoring in an anticipated refund of around $60 million from the U.S. government.

1 month ago · zacks.com

Alcon (ALC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Alcon (ALC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.